This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Bebetter Med Inc.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Shiqing Zhou: Innovator in Anti-Tumor Drug Development
Introduction
Shiqing Zhou is a notable inventor based in Guangdong, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating cancer. His innovative work focuses on creating targeted therapies that can effectively combat specific mutations in cancer cells.
Latest Patents
Shiqing Zhou holds a patent for a compound known as 2,4-bis(nitrogen-containing group)-substituted pyrimidine. This compound is represented by a general formula (I) and includes a preparation method and its use in anti-tumor drug development. The compound selectively suppresses the activity of mutant epidermal growth factor receptors (EGFR), including the T790M mutation, which is often associated with non-small cell lung cancer (NSCLC). This innovation has the potential to lead to more effective treatments for patients with specific EGFR mutations.
Career Highlights
Zhou is currently associated with Bebetter Med Inc., where he continues to advance his research in the pharmaceutical sector. His work is characterized by a strong focus on developing drugs that target specific genetic mutations, thereby improving treatment outcomes for cancer patients.
Collaborations
Shiqing Zhou collaborates with esteemed colleagues such as Changgeng Qian and Weicai Xue. These partnerships enhance the research and development efforts at Bebetter Med Inc., fostering an environment of innovation and scientific discovery.
Conclusion
Shiqing Zhou's contributions to the field of anti-tumor drug development exemplify the impact of targeted therapies in modern medicine. His innovative work holds promise for improving treatment options for patients with challenging cancer mutations.